Phase II trial of gallium nitrate in patients with advanced malignant melanoma.
A phase II trial of gallium nitrate (250-300 mg/m2/day for 7 consecutive days) was conducted in patients with metastatic melanoma. Therapy was well-tolerated, but only one of 31 evaluable patients experienced a partial regression. Further evaluation of gallium nitrate at this dose and schedule is not warranted in patients with malignant melanoma.
D000008:Abdominal Neoplasms / Q000556:secondary; D000328:Adult; D000368:Aged; D002118:Calcium / Q000097:blood; D003404:Creatinine / Q000097:blood; D004341:Drug Evaluation; D004573:Electrolytes / Q000097:blood; D005260:Female; D005708:Gallium / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D007263:Infusions, Parenteral; D008297:Male; D008545:Melanoma / Q000000981:diagnostic imaging / Q000188:drug therapy*; D008875:Middle Aged; D009325:Nausea / Q000139:chemically induced; D009362:Neoplasm Metastasis; D011877:Radionuclide Imaging; D012878:Skin Neoplasms / Q000000981:diagnostic imaging / Q000188:drug therapy*
D004573:Electrolytes; D003404:Creatinine; D005708:Gallium; D002118:Calcium; C027235:gallium nitrate